The past decade has seen a significant positive evolution in the field of immuno-oncology (IO). The introduction of checkpoint inhibition therapies and adoptive cell transfer therapy (ACT) resulted in some excellent improvements in five-year survival rates in patients with hematologic cancers, as well as in certain patients with solid tumors. The first checkpoint-inhibiting antibody therapies have been approved by the U.S.…